Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.47 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CDYL2 | Q8N8U2 | 6/20 | 0.46 |
| ▸ | CDYL | Q9Y232 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403282 | 0.94 | MEN1 (0.58) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| SCHEMBL6399169 | 0.93 | KMT2A (0.57) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| SCHEMBL6399164 | 0.93 | KMT2A (0.57) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| SCHEMBL6399497 | 0.92 | MEN1 (0.55) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| SCHEMBL5722010 | 0.92 | KMT2A (0.55) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| Bromide SCHEMBL6010196 | 0.91 | MEN1 (0.56) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| Bromide SCHEMBL6074278 | 0.91 | MEN1 (0.56) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| SCHEMBL10531115 | 0.85 | MAPT (0.48) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| Iodide SCHEMBL10531094 | 0.84 | MAPT (0.47) | MEN1RECQLKMT2AHDAC3HDAC4 | |
| Bromide SCHEMBL3853588 | 0.84 | MAPT (0.50) | MEN1RECQLKMT2AHDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1554253-A4 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-09-20 | — | — | EP | disclosed |
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-12-08 | — | — | US | disclosed |
| EP-1554253-A1 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6890894-B2 | Fatty acids, soaps surfactant systems, and consumer products based thereon | THE PROCTER & GAMBLE COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040092418-A1 | Fatty acids, soaps surfactant systems, and consumer products based thereon | CONNOR DANIEL STEDMAN (US) | 2004-05-13 | — | — | US | disclosed |
| WO-2003101970-A1 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272936-A1 | Imidazolium cxcr3 inhibitors | CXCR3, CXCR1, CCR7 | MEN1 3721/4885RECQL 1290/4885KMT2A 4040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.